The goal of this study was to increase CD93, CD40L, and CXCL13 transgene expression, modify antibiotic resistance, and optimize manufacturing in lentiviral packaging by modifying transduction parameters, transgene orientation, Multiplicity of Infection (MOI), promoters, and post-transcriptional regulatory elements. The gene discussed is CD93; the disease is infection.